Recombinant Human CRTAM Protein, His Tag, 100 µg

Background
Class I-restricted T cell-associated molecule (CRTAM), a member of nectin family and the immunoglobulin superfamily, is also known as cytotoxic and regulatory T-cell molecule, which is expressed by activated CD8+ and NK T cells. CRTAM is found in spleen, thymus, small intestine, peripheral blood, and surprisingly, in brain where it is highly expressed by Purkinje cells of the cerebellum. The high affinity of CRTAM/IGSF4 adhesion allows CRTAM to disrupt IGSF4 homotypic interactions (3 - 5). IGSF4 and T cell receptor co-engagement of CRTAM-expressing CD8+ cells induces increased IFN-gamma or IL-22 production (3, 4). Furthermore, a role in cancer surveillance through NK cell-mediated rejection of IGSF4-expressing tumors has been proposed.

Source
Recombinant Human CRTAM, His Tag (CRM-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ser 18 - Gly 287 (Accession # O95727-1).
Predicted N-terminus: Ser 18

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 31.9 kDa. The protein migrates as 45-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet

Clinical and Translational Updates

(1) "Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort"
Liu, Kramer, Sandulache et al
Cancer Res (2022)
(2) "Identification and Validation of Hub Genes for Predicting Treatment Targets and Immune Landscape in Rheumatoid Arthritis"
He, Yin, Yu et al
Biomed Res Int (2022) 2022, 8023779
(3) "CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions"
Murayama, Ikegami, Kamekura et al
Front Immunol (2022) 13, 941385
Showing 1-3 of 71 papers.